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Abstract		 While	the	rate	at	which	resistance	develops	against	antimicrobials	rises,	research	and	development	for	new	antimicrobials	declines.		By	placing	selective	pressure	on	bacteria	we	are	inadvertently	forcing	bacteria	into	expressing	and	propagating	genes	conferring	high	levels	of	resistance.	Continued	misuse	and	overuse	of	antibiotics,	in	light	of	the	evident	problem	developing,	must	be	resolved.	To	find	a	resolve,	a	multidisciplinary	and	multifaceted	approach	must	be	taken	which	involves	1)	research	and	development	of	novel	antimicrobial	agents	and	2)	governmental	regulation.			Strides	in	new	antimicrobial	drug	development	largely	revolve	around	making	old	antibiotics	usable	again.	Resistance-Modifying	Agents	(RMAs)	act	to	re-sensitize	resistant	bacteria	to	antibiotics	through	a	variety	of	mechanisms,	although	currently	most	target	bacterial	resistance	mechanisms	themselves,	such	as	β	-lactamases.	Foreseeably,	while	these	compounds	have	shown	efficacy	and	certainly	are	of	value	in	the	present	crisis,	it	is	a	short-term	solution	in	light	of	the	evidently	rapid	and	dynamic	capability	of	bacteria	to	respond	evolutionarily.	Nonetheless,	a	new	class	of	RMAs,	currently	being	researched	and	developed	at	Wang	lab,	hope	to	extend	RMA	lifespan	through	a	model	of	synthetic	compound	development	that	targets	gene	expression.	Both	clinically	and	community-acquired	resistance	contribute	to	the	demolishment	of	a	critical	building	block	(antibiotics)	of	modern	medicine.	Arguably	the	most	nonsensical	piece	of	the	puzzle	is	subtherapeutic	antibiotic	use	in	livestock,	which	accounts	for	80%	of	all	antibiotic	use	in	the	United	States12.	FDA	regulations	
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are	seemingly	the	only	feasible	way	to	fix	the	problem,	and	yet	their	efforts	in	recent	regulatory	measures	not	only	contain	major	loopholes,	but	seem	altogether	to	be	largely	barren	of	any	significant	resolutions.			 	
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Terms	and	Definitions	
	
CFU:	Colony	Forming	Unit		
The	FD&C	Act:	Federal	Food,	Drug,	and	Cosmetic	Act,	is	a	set	of	laws	that	allows	the	Food	and	Drug	Administration	(FDA)	to	regulate	food	and	drugs	in	the	United	States.	It	was	passed	by	congress	in	1938	and	is	what	gives	FDA	their	authority.		
GI50:	GI50	is	the	concentration	at	which	the	compound	must	be	at	to	inhibit	50%	of	cell	proliferation.	This	is	a	measure	of	the	compound’s	toxicity	to	human	cells.	The	higher	the	number,	the	less	toxic	the	compound	is.		
Medically	Important:	FDA	ranked	each	antibiotic	as	medically	important	(to	human	health)	or	not.	This	ranking	was	based	upon	the	probability	of	transference	of	resistant	bacteria	from	animal	to	human,	and	the	subsequent	consequences	if	a	human	were	to	be	exposed	to	resistant	bacteria	(GIF	#152	20).		
MIC:	MIC,	or	the	Minimum	Inhibitory	Concentration,	represents	the	current	resistance	level	of	the	bacteria	to	a	particular	antibiotic.		
MRC:	MRC,	or	Minimum	Resensitizing	Concentration,	is	the	concentration	of	the	compound	(with	some	antibiotics)	at	which	no	overnight	growth	is	observed.	The	lower	the	number	the	better.		
Multidrug-resistant:	“Multidrug-resistant	means	that	the	associated	bacterial	illness	can	no	longer	be	cured	by	at	least	three	different	classes	of	antibiotics.”1		
Nosocomial:	A	disease	originating	in	a	hospital	or	contracted	from	medical	care.	Also	termed	“hospital-acquired”.		
RMA:	Resistance-modifying	agents	(RMAs)	specifically	target	non-essential	bacterial	genes	that	are	responsible	for	the	expression	of	bacterial	resistance	mechanisms	(e.g.	resistance-conferring	genes)	and	their	products.	They	act	synergistically	with	antibiotics,	but	do	not	exhibit	antibacterial	activity	on	their	own.		
SAR:	A	SAR,	or	Structure-Activity	Relationship	study,	is	the	process	of	making	slight	modifications	to	the	compound	to	yield	a	variety	of	analogues.	These	analogues	can	lead	to	more	potent	compounds	and	reveal	what	parts	of	the	structure	are	most	important	to	its	activity.	In	performing	a	structure-activity	relationship	study,	the	basic	data	to	determine	the	compound’s	activity	include	MIC,	MRC,	as	well	as	GI50,	a	measure	of	mammalian	cell	toxicity.	 		 	
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CHAPTER	1:	Clinically-Acquired	Resistance	and	the	Development	of	Novel	
Resistant-Modifying	Agents	
1.1 Introduction	&	Background	
1.1.1	Introduction		While	we	have	developed	advanced	surgery	techniques	to	replace	hips	and	create	bionic	legs,	it	may	be	forgotten	that	all	of	these	advances	would	be	rendered	useless	without	the	ability	to	fight	infections	with	antibiotics.	Antibiotics	are	a	lynchpin	in	modern	medicine,	and	now	they	are	ceasing	to	work.	Overuse	and	misuse	of	antibiotics	in	the	community	and	clinic	are	leading	us	toward	an	era	that	those	living	today	have	only	read	of	in	history	books	(Photo	1.1),	an	era	describing	life	when	morbidity	and	mortality	were	much	of	the	same.	Low-level	resistance	is	rising	across	the	population	through	community-acquired	means,	such	as	antibiotic	use	in	agriculture.	Imminently,	the	strength	and	frequency	of	clinically-acquired	multi-drug	resistant	bacteria	is	escalating.	Based	of	a	2013	report	from	the	CDC,	it	is	estimated	that	antibiotic	resistance	causes	at	a	minimum	over	2	million	illnesses	and	23	thousand	deaths	annually	in	the	United	States1.	While	the	rate	at	which	resistance	develops	against	antimicrobials	rises,	research	and	development	for	new	antimicrobials	
Photo	1.1.	A	syphilis	sufferer	before	the	days	of	
antibiotic	treatment.	bbc.co.uk.	Web.	12.2.2016.	
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declines.		Continued	misuse	and	overuse	of	antibiotics,	in	light	of	the	evident	problem	developing,	must	be	resolved.	To	find	a	resolve,	a	multidisciplinary	and	multifaceted	approach	must	be	taken.	Firstly,	research	and	development	of	novel	antimicrobial	agents	must	flourish	since	resistance	will	continually	develop1.	Secondly,	governmental	regulation	must	step	in	to	discontinue	antibiotic	misuse	in	agriculture	and	livestock.		And	finally,	the	conception	of	antibiotics	bearing	little	consequence	must	shift	in	the	minds	of	clinicians	and	the	public,	so	as	to	treat	antibiotics	as	serious	drugs	with	global	side-effects.		
1.1.2	The	History	of	Antibiotics	in	Clinical	Applications	The	first	antibiotic,	penicillin,	was	discovered	by	Alexander	Fleming	in	1928,	and	won	him	a	noble	prize	in	1945.	Here	is	an	excerpt	from	his	Nobel	lecture	on	December	11,	1945:	“But	I	would	like	to	sound	one	note	of	warning…It	is	not	difficult	to	make	microbes	resistance	to	penicillin	in	the	laboratory	by	exposing	them	to	concentrations	not	sufficient	to	kill	them,	and	the	same	thing	has	occasionally	happened	in	the	body.	The	time	may	come	when	penicillin	can	be	bought	by	anyone	in	the	shops.	Then	there	is	a	danger	that	the	ignorant	man	may	easily	underdose	himself	and	by	exposing	his	microbes	to	non-lethal	quantities	of	the	drug	make	them	resistant.”2	(Figure	1.1).	Now,	a	century	later,	can	we	still	claim	ignorance?	Although	the	discovery	of	antibiotics	was	simultaneous	with	the	discovery	of	antibiotic	resistance,	few	heeded	the	latter.	Indeed	penicillin	unveiled	a	golden	age	
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in	medicine,	where	there	was	no	foreseen	downside	to	prescribing	what	was	seemingly	a	miracle	drug.	As	Fleming	put,	“[antibiotics]	to	all	intents	and	purposes	[are]	non-poisonous	so	there	is	no	need	to	worry	about	giving	an	overdose	and	poising	the	patient”2.	Furthermore,	the	applications	of	antibiotic	were	truly	expansive,	curing	the	deadly	and	the	dreadful:	scarlet	fever,	Tuberculosis,	and	
Figure	1.1.	Antibiotic	Resistance	Schema.	Frieden,	Tom.	"Antibiotic	resistance	threats	in	the	United	
States,	2013."	Centers	for	Disease	Control	and	Prevention,	US	Department	of	Health	and	Human	
Services	(2013).	
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syphilis	(Photo	1.1)	to	name	a	few.	Open-heart	surgery	and	aggressive	chemotherapy	for	cancers	such	as	leukemia	became	possible	as	antibiotics	greatly	reduced	the	risk	of	infection3.			In	lieu	of	such	a	‘miraculous’	discovery,	antibiotics	were	over-prescribed	with	a	carefree	zeal.	For	instance,	dentists	gave	antibiotics	to	people	with	heart	murmurs	for	the	extremely	unlikely	case	of	a	bacterial	infection;	and	children	with	ear	infections	were	given	antibiotics	without	running	tests	to	find	out	if	it	was	bacterially	caused,	which	was	less	likely	than	not	(80%	were	virally	caused)3.	As	one	could	imagine,	a	residual	affect	of	such	cavalier	prescribing	is	that	there	is	still	a	widely	favored	belief	among	patients	worldwide	that	it’s	reasonable	to	take	antibiotics	at	any	hint	of	illness;	this	is	particularly	problematic	in	many	parts	of	the	world	where	antibiotics	require	no	prescription.	Nonetheless,	in	countries	that	do	require	a	prescription,	patients	often	voluntarily	request	antibiotics	from	doctors,	who	often	oblige	given	the	demands	of	rapid	patient-visit	turnover,	the	precarious	legal	climate	currently	in	healthcare,	and	the	relatively	time-consuming	nature	of	bacterial	laboratory	testing3.	To	note,	on	the	other	side	of	this	same	issue,	there	is	some	grounded	reasoning	as	to	why	you	would	prescribe	antibiotics	“just	in	case”.	For	instance,	in	ICUs	(Intensive	Care	Units)	there	is	a	positive	relationship	between	mortality	due	to	sepsis	and	every	hour	a	bacterial	infection	is	left	untreated4.	As	a	result	this	evidence	favors	a	heavy	hand	in	precautionary	antibiotic	distribution	before	obtaining	the	results	of	patient	cultures.	
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Today,	in	the	United	States	80%	of	all	antibiotics	are	used	for	non-human	purposes5	that	foster	the	development	of	resistant	bacteria	in	our	food	supply.	Furthermore,	the	CDC	estimates	that	up	to	50%	of	antibiotics	prescribed	in	the	clinical	setting	are	unnecessary	or	“not	optimally	effective	as	prescribed”1.	The	rate	of	resistance	developing	in	bacteria	is	increasing	and	far	surpasses	humans’	capacity	to	develop	new	antibiotics;	since	1996,	resistance	to	new	antibiotics	approved	by	The	U.S.	Food	and	Drug	Administration	(FDA)	usually	appears	within	a	year1,6	and	the	number	of	new	antibacterials	approved	by	the	FDA	dwindles	(Figure	1.2).There	is	little	research	into	new	antibiotics	given	the	need;	this	is	for	several	reasons.	Foremost,	large	pharmaceutical	companies	see	little	profit	in	the	development	of	antibiotics.	As	antibiotics	have	developed	over	time,	resistance	has	emerged	increasingly	quickly	to	new	antibiotics.	Aside	from	foreseen	resistance	to	new	antibiotics	forecasting	a	short	market	lifespan,	likely	the	primary	reason	for	the	lack	of	antibiotic	development	in	big	pharmaceutical	companies	is	in	the	curative	
Figure	1.2.	Reverse	development	of	new	antibiotics	versus	resistant	
bacteria.	The	abscissa	shows	a	time	bar.	The	ordinate	shows	blue	bars	that	
indicate	the	number	of	antibiotics	launched	in	the	depicted	period;	the	red	
line	shows	the	percentage	of	bacteria	resistant	against	the	last	resort	
antibiotic	vancomycin	in	US	hospital	intensive	care	units;	the	black	line	
shows	a	moving	average	trend	line	of	antibiotics	launched	in	the	depicted	
period.	The	number	of	antibiotic-resistant	bacteria	infections	is	increasing	
whereas	the	development	of	new	antibiotics	is	constantly	decreasing.	
Schäberle,	Till	F.,	and	Ingrid	M.	Hack.	"Overcoming	the	current	deadlock	in	
antibiotic	research."	Trends	in	microbiology	22.4	(2014):	165-167.		
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nature	of	antibiotics.	Curative	drugs	are	less	profitable	than	drugs	designed	for	chronic	use	(such	as	drugs	to	treat	blood	pressure,	statins,	and	antacids).		In	addition,	the	merging	of	pharmaceutical	companies	has	resulted	in	less	diversified	research	teams7.			
1.2	Antibiotics	While	hundreds	of	compounds	exhibiting	antibiotic	activity	have	been	isolated	over	the	years,	few	of	these	may	be	used	clinically	because	many	compounds	have	inacceptable	levels	of	toxicity	to	human	cells	(GI50)	or	lack	physicochemical	properties	that	allow	them	to	function	well	in	the	human	body	(such	as	hydrophilicity).	Antibiotics	that	may	be	used	clinically	share	one	of	a	few	mechanisms	of	action,	which	largely	correlate	to	differences	between	bacterial	cells	and	human	cells.			
1.2.1	Cell	Wall	Synthesis	and	Penicillin-Binding	Proteins	The	first	mechanism	applies	to	bacterial	cell-wall	synthesis;	bacteria	have	cell	walls	made	of	peptidoglycan,	a	sugary	amino-acid	mesh	around	the	plasma	membrane;	human	cells	do	not	share	this	feature.	Gram-negative	bacteria	have	an	additional	“outer”	plasma	membrane	exterior	to	the	cell	wall,	generally	making	them	more	elusive	targets	amongst	human	cells	(compared	to	gram-positive	bacteria).	Commonly	proteins	known	as	penicillin	binding	proteins	(PBPs)	are	responsible	for	the	final	stages	of	assembling	the	cellular	wall	by	cross-linking	polymers	(Figure	1.3,	part	1-3);	more	simply,	they	may	be	imagined	as	a	functioning	
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similar	to	zippers,	acting	to	zip	pieces	of	wall	together.	The	name	“Penicillin	Binding	Proteins”	comes	from	enzymes	in	this	class	having	a	high	affinity	for	penicillin.	This	feature	has	been	heavily	extorted	with	β-lactam	antibiotics,	which	serve	to	effectively	bind	to	the	PBP’s	active	site(s),	inhibiting	the	enzyme’s	transpeptidase	activity	(its	ability	to	cross-link	the	adjacent	tetrapeptides	chains);	essentially	the	β-lactam	antibiotic	serves	to	jam	the	“zippers”	(Figure	1.3,	part	4,5).	If	enough	of	the	zippers	are	jammed,	the	integrity	of	cell	wall	gives	and	the	cell	dies	via	lysis.	Different	bacteria	express	a	variety	of	PBPs,	most	having	somewhere	between	4-20	types8.		Co-expressed	PBPs	serve	different	functions,	although	not	all	are	fully	understood	yet.	Commonly	there	are	two	general	classes	of	PBPs	that	are	differentiated	by	molecular	weight	(high	and	low	molecular	mass).	Of	the	PBPs	that	have	been	thoroughly	investigated,	such	as	those	of	E.	Coli,	it	appears	that	inhibition	of	any	single	type	of	PBP	does	not	disable	cell-wall	synthesis	lethally8.		
Figure	1.3.	PBPs	catalyze	the	cross-linking	of	
the	bacterial	cell	wall	(1,2,3).	Penicillin	and	
other	β-lactam	antibiotic	act	by	irreversibly	
binding	and	permanently	inhibiting	the	PBP	
(4,5).	"Penicillin	Binding	Proteins."	Wikipedia.	
Wikimedia	Foundation,	n.d.	Web.	21	Feb.	
2016.	
	 9	
1.2.2	Membrane	Permeability	A	second	mechanism	of	action	involving	the	cell	wall,	although	less	common,	is	seen	through	a	family	of	antibiotics	known	as	lantibiotics.	The	most	well-known	member	of	this	family	is	Nisin,	which	acts	on	gram-positive	bacteria.	Nisin’s	function	is	two-fold;	1)	It	binds	to	an	essential	membrane-bound	cell-wall	precursor	(lipid	II);	this	inhibits	transglycosylation,	a	step	in	cell	wall	synthesis;	2)	then,	it	forms	pores	in	the	membrane	below,	increasing	the	permeability	of	the	membrane	1000-fold,	which	ultimately	leads	to	cell	death9.	The	outer	membrane	of	gram-negative	bacteria	inhibits	lantibiotic’s	access	to	lipid	II,	and	therefore	lantibiotics	cannot	be	used	with	gram-negative	bacteria.	Interestingly,	while	Nisin	has	been	used	for	50	years,	little	resistance	has	developed	against	it10.	Of	the	resistance	that	has	been	seen	against	Nisin,	a	correlation	with	increased	expression	of	certain	PBPs	in	combination	with	a	histadine	kinase	is	evident,	but	the	mechanistic	link	is	still	unknown8.				
1.2.3	Protein	Synthesis	at	Intracellular	Ribosomes	A	third	mechanism	of	action	targets	protein	synthesis	at	intercellular	ribosomes.	While	both	humans	and	bacteria	have	similarly	functioning	ribosomes,	they	are	different	sizes.	This	size	difference	is	exploited	by	introducing	antibiotics	that	prefer	to	bind	to	50S	or	30S	ribosomal	units	(as	oppose	to	the	40S	or	60S	subunits	in	human	cells).	Several	classes	of	antibiotics	target	protein	synthesis,	however	their	mechanisms	are	slightly	different.	Although	it	is	widely	resisted	among	bacteria,	Erythromycin	is	a	macrolide	that	can	grow	to	high	concentrations	
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in	gram-positive	bacteria;	it	functions	by	reversibly	binding	to	the	50S	ribosome	unit,	inhibiting	movement	along	mRNA.	Similarly,	Chloramphenicol	and	Clindamycin	bind	to	the	50S	subunit	and	inhibit	peptide	elongation;	specifically	through	inhibition	of	the	peptide	bond	formation	between	amino	acids.	Alternatively,	there	are	classes	of	antibiotics	that	target	the	30S	ribosomal	subunit.	Streptomycin,	an	aminoglycoside	and	effective	antibiotic	against	gram-negative	bacteria,	allosterically	irreversibly	binds	to	the	30S	subunit,	causing	a	slight	conformational	change	in	the	protein	that	causes	the	mRNA	to	be	misread.	Likewise,	tetracyclines	bind	to	the	30S	subunit	and	interfere	with	anticodon-codon	reading	by	blocking	tRNA	from	binding	to	the	ribosome11,12.		
1.	3	The	Emergence	of	Antibiotic	Resistance	Epidemiologically,	the	first	documented	nosocomial	infections	due	to	multi-drug	resistant	bacteria	can	be	traced	back	to	independent	bacterial	outbreaks	in	several	areas	of	the	world	such	as	Turkey,	England,	and	French	Guiana.	Interestingly,	several	of	the	outbreaks	developed	in	neonatal	units.	That	the	outbreaks	(and	associated	antibiotic	resistance)	were	in	neonatal	units	provides	a	model	for	how	antibiotic	resistance	can	develop	from	selective	pressure.	Due	to	undeveloped	immunity	in	neonates,	bacterial	infections	are	particularly	threatening.	As	a	result,	and	likely	in	combination	with	high-levels	of	concern	around	the	care	of	newborns,	it	has	been	commonplace	to	put	neonates	on	broad-spectrum	antibiotics	for	extended	periods	of	time.	Studies	such	as	De	Man,	et	al.	have	shown	that	broad-spectrum	antibiotic	therapy	is	much	more	likely	(18-fold)	to	select	for	resistant	
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(especially	multi-drug	resistant)	bacteria	than	narrow-spectrum	antibiotic	therapy13.		Furthermore,	the	use	of	antibiotics	for	extended	periods	of	time	contributes	to	the	development	of	resistant	bacteria	due	to	killing	off	of	nearly	all	variety	of	bacteria,	aside	from	ones	conferring	resistance	mechanisms.	As	a	result,	resistant	bacteria	proliferate	and	saturate	the	environment.	As	put	by	D.	Isaacs	in	a	review	article,	such	treatment	could	be	seen	as	“unnatural	selection”	for	resistant	bacteria14.	Most	bacteria	already	have	resistance	genes	in	their	chromosomal	make-up,	as	was	discovered	by	a	group	of	scientists	studying	bacteria	from	30,000	years	ago15.	With	recent	selective	pressure,	these	genes	have	begun	to	be	expressed	more	frequently.	The	study	by	D’Costa,	et	al.	postulates	that	“new	antibiotics	will	select	for	pre-existing	resistant	determinants	that	have	been	circulating	the	microbial	pangenome	for	millennia,”	and	suggests	that	for	each	antibiotic	existing	in	nature,	discovered	or	not,	exists	simultaneously	an	antagonistic	resistance	determinate15.	In	essence,	when	an	antibiotic	emerges	in	nature,	so	does	its	resistance	determinant	(or	shortly	thereafter).	
1.4	TYPES	OF	RESISTANCE	MECHANISMS	and	RMA	targets	
	
Figure	1.4.	Mechanisms	of	Antibiotic	Resistance.	Gullberg,	DR.	E.	"Resistance	
Mechanisms	in	Bacteria."	Www.reactgroup.org.	N.p.,	n.d.	Web.	18	Feb.	2016.	
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Given	the	lack	of	development	of	new	antibiotics	and	the	difficultly	in	doing	so,	one	popular	idea	of	combating	antibiotic	resistance	is	through	making	already-developed	antibiotics	useful	again.	Theoretically	this	could	be	accomplished	by	targeting	the	resistant-mechanisms	that	are	rendering	the	antibiotics	useless.	There	are	several	common	techniques	bacteria	use	to	resist	antibiotics;	alteration	of	target	site,	enzymatic	degradation,	efflux	pumps,	and	reduced	permeability	(Figure	1.4).	An	important	area	of	research	is	the	development	of	compounds	that	specifically	target	these	mechanisms.	These	compounds,	termed	Resistance	Modifying	Agents	(RMAs),	act	synergistically	with	antibiotics,	but	do	not	exhibit	antibacterial	activity	on	their	own	(Figure	1.5).	The	general	idea	is	to	create	a	compound	to	combine	with	current	antibiotics	(which	are	already	streamlined	for	production)	to	create	a	new	“cocktail”	antibiotic.	The	concept	of	cocktail	treatments	is	not	new;	it	is	common	practice	in	the	fight	against	cancer	and	viral	infections	such	as	HIV.	For	antibiotics,	the	cocktail-approach	would	increase	the	market	life	span	of	current	antibiotics,	which	would	appeal	to	pharmaceutical	companies	and	people	in	the	health	sector.	
Figure	1.5.	General	example	of	RMA	function.	A)	The	antibiotic		
(purple)	effectively	binds	to	target	and	cell	death	ensues.	B)	
Bacterial	alteration	of	target	site	inhibits	antibiotic	binding.	C)	
An	RMA	(yellow)	is	added	in	conjunction	with	the	antibiotic;	
the	RMA	causes	bacterial	target	to	be	sensitive	to	antibiotic	
again,	bacteria	is	once	again	tolerant	to	the	antibiotic.	Hodzic,	
Emir.	"Lyme	Borreliosis:	Is	there	a	preexisting	(natural)	
variation	in	antimicrobial	susceptibility	among	Borrelia	
burgdorferi	strains?."	Bosnian	Journal	of	Basic	Medical	Sciences	
15.3	(2015):	1.	
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1.4.1	Alteration	of	Target	Site	New	resistance	mechanisms	develop	through	a	series	of	point	mutations,	in	which	those	mutations	that	provide	an	advantage	to	the	bacteria	are	propagated	through	the	population	over	time.	This	basic	schema	of	evolution	and	natural	selection	is	not	unlike	human	evolution;	the	key	difference	is	the	rate	of	bacterial	evolution.	For	instance,	in	our	time-kill	experiments,	we	measured	the	growth	of	multi-drug	resistant	BAA44,	a	MRSA	strain,	and	found	that	the	bacterial	population	doubles	every	8	minutes	and	28	seconds1.	This	rapid	reproduction	and	population	growth	allows	for	natural	selection	to	occur	with	dynamic	responsiveness,	being	on	a	temporal	scale	much	faster	than	our	own.	Favorable	point	mutations	can	quickly	become	common	in	a	single	population.		A	frequent	resistant	mechanism	of	bacteria,	albeit	somewhat	unintentional,	is	alteration	of	the	binding	site	where	the	antibiotic	attaches	(such	as	on	a	PBP)	so	that	it	no	longer	binds	to,	or	binds	with	less	affinity	to,	the	antibiotic.	This	often	occurs	through	the	propagation	of	favorable	point	mutations	that	cause	conformational	changes	to	the	active	site,	or	result	in	an	amino	acid	substitution	in	the	active	site	that	is	less	favorable	for	binding.	For	instance,	the	portion	of	DNA	coding	for	a	certain	PBP	may	have	a	point	mutation	that	results	in	the	active	site	having	a	lower	affinity	for	β-lactam	antibiotics;	as	is	the	case	for	the	well-known	PBP,	PBP2a.	Such	mutations	could	be	propagated,	mutate	again,	and	eventually																																																									1	Based	off	the	rate	equation	P(t)=Piekt	where	Pi	is	the	initial	population,	k	is	the	growth	coefficient,	and	t	is	the	time	in	hours.	OD	was	measured	at	t=0	and	t=24	hours;	OD	was	converted	to	CFUs	using	a	standard	curve	we	empirically	derived.	Conditions	of	growth	were	37°C	in	MHB	solution.	
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result	in	the	active	site	losing	all	binding	affinity	for	the	antibiotic.	The	mutation	of	antibiotic	target	sites	is	a	leading	problem	for	resistance	against	antibiotics	targeting	intracellular	ribosomes16.		
1.4.2	Enzymatic	Degradation:	β-lactamases	Enzymatic	degradation	of	the	antibiotic	is	most	widely	known	through	β-lactamases,	which	are	the	first	line	of	resistance	against	β-lactam	antibiotics.	β-lactamases	are	enzymes	that	hydrolyze	the	defining	and	functionally	essential	β-lactam	ring	structure	shared	by	all	β-lactam	antibiotics.	As	β-lactam	antibiotics	are	one	of	the	largest	and	most	valuable	classes	of	antibiotics,	much	research	has	gone	into	the	re-sensitization	of	bacteria	to	β	-lactam	antibiotics.	While	β-lactamases	can	be	sorted	into	several	broad	categories,	there	are	hundreds	of	variants	β-lactamases	due	to	point	mutations	resulting	in	slightly	altered	amino	acid	residues	in	the	active	sites.	The	frequency	and	culmination	of	these	point	mutations	makes	identifying	and	combating	β	-lactamases	particularly	challenging.	Additionally,	with	horizontal	gene	transfer,	the	issue	becomes	even	more	convoluted.		A	previous	(and	notably	successful)	development	for	re-sensitizing	bacteria	to	β-lactam	antibiotics	has	been	β-lactamase	inhibitors.	Essentially	an	inhibitor	shares	structural	features	with	the	antibiotic,	such	as	the	β	-lactam	ring,	and	fits	into	the	active	site	of	the	resistance-conferring	(hydrolyzing)	enzyme	(β-lactamase).	The	inhibitor’s	irreversible	binding	and	occupation	of	the	enzyme’s	active	site	permanently	disables	it.	While	this	system	has	shown	some	efficacy,	resistance	has	
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developed.	Since	one	inhibitor	binds	irreversibly	to	one	enzyme,	it	would	make	sense	that	this	system	of	inhibition	functions	in	a	one-to-one	inhibitor-to-enzyme	ratio.	Resistance	develops	from	up-regulation	of	enzymatic	gene	expression;	ultimately	the	resistance-conferring	enzymes	will	be	left	to	hydrolyze	the	antibiotic	if	the	number	of	enzymes	outweighs	the	number	of	inhibitors.	The	development	of	resistance	to	β-lactamase	inhibitors,	as	seen	with	Clauvonic	Acid,	speaks	to	the	inevitability	of	bacteria	developing	resistance	mechanisms	to	antibiotics	and	inhibitors.		
1.4.3	Efflux	Pumps	Bacteria	can	also	up-regulate	expression	of	efflux	pumps;	this	essentially	causes	antibiotics	that	enter	the	cell	to	be	pumped	back	out	before	they	exert	their	effects.	This	mechanism	is	particularly	effective	for	bacteria	and	is	a	major	contributor	to	multi-drug	resistance.	Often	the	efflux	pumps	lack	specificity;	this	plays	to	the	bacteria’s	advantage	because	a	pump	can	expel	a	variety	of	products	(e.g.	antibiotics)	ranging	in	class	and	structure16.	RMAs	targeting	efflux	pumps	could	greatly	aid	in	increasing	antibiotic	sensitivity	to	a	number	of	clinically	relevant	multidrug	resistant	bacteria16.			
1.4.4	Membrane	Permeability	A	common	point	of	entrance	(porins)	for	antibiotics	aiming	to	act	intracellularly	may	be	altered	or	expression	down-regulated	so	that	the	antibiotics	cannot	enter	into	the	bacterial	cell.	This	is	largely	important	in	gram-negative	
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bacteria,	which	have	an	additional	outer	plasma	membrane	(exterior	to	the	cell	wall),	generally	making	them	more	elusive	targets	amongst	human	cells	and	more	difficult	to	penetrate	with	antibiotics.	Overall	gram-negative	bacteria	are	considered	particularly	dangerous	in	infectious	disease	and	reduction	in	permeability	can	result	in	reduced	uptake	of	antibiotics.		
1.4.5	Escalating	Resistance	Levels	Once	a	bacterial	resistance	mechanism	is	expressed,	the	bacteria	may	up-regulate	or	down-regulate	the	expression	of	these	genes	under	selective	pressure,	such	as	antibiotics.	For	instance	bacteria	may	up-regulate	the	production	of	β-lactamases	in	the	presence	β-lactam	antibiotics;	this	can	make	it	more	challenging	to	overcome	resistance	in	cases	such	as	β-lactamases	and	β-lactamase	inhibitors.			Ultimately	however,	the	primary	mechanism	of	widespread	genetic	antibiotic	resistance	is	through	horizontal	gene	transfer	including	conjugation,	transduction	and	transformation	(Figure	1.6).	Essentially,	once	a	resistance	mechanism	is	developed	in	bacteria,	this	resistance	can	be	shared,	most	commonly	though	plasmids,	to	other	bacteria.	This	is	particularly	problematic	because	bacteria	can	become	multi-drug	resistant	very	quickly	as	they	share	and	pick-up	resistance	mechanisms	from	neighboring	bacteria.	Many	plasmids	evolve	to	carry	DNA	for	multiple	resistance	mechanisms	(often	all	of	which	are	passed	during	conjugation)17;	this	is	one	factor	suggesting	that	DNA	resistance-conferring	genes	are	quite	close	(physically)	on	the	bacterial	chromosome.		
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As	an	example,	CTX-M-15,	a	β-lactamase	that	originated	from	a	strain	of	E.	Coli	and	has	extended	spectrum	β-lactamase	(ESBL)	activity	(meaning	it	has	activity	against	most	β-lactam	antibiotics)	has	spread	worldwide	to	other	members	of	Enterobacteriaceae,	a	large	family	of	gram-negative	bacteria.	This	is	particularly	concerning	as	pathogenic	Enterobacteriaceae	are	often	associated	with	high	levels	of	resistance,	even	to	Carbapenems,	which	are	considered	“the	last	resort	for	treatment	of	serious	gram-negative	infections”1.	The	wide-scale	presence	of	CTX-M-15	is	likely	to	have	been	passed	through	conjugation,	as	it	is	often	found	on	IncFII	plasmids,	which	are	highly	active	and	associated	with	the	genetic	material	of	E.	Coli.		
Figure	1.6.	Three	methods	of	horizontal	gene	transfer	conferring	bacterial	resistance.	Hanselaar,	
Coen.	"Frontiers	in	Medical	Biology	I."	Frontiers	in	Medical	Biology	I.	N.p.,	n.d.	Web.	21	Feb.	2016.	
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1.4.6	A	New	Class	of	Resistance-Modifying	Agents	Resistance-modifying	agents	(RMAs)	specifically	target	bacterial	non-essential	genes	that	are	responsible	for	the	expression	of	bacterial	resistance	mechanisms	(e.g.	resistance-conferring	genes)	and	their	products.	As	of	yet,	the	RMAs	used	clinically	target	a	specific	bacterial	resistant	mechanism	(e.g.	degrading	enzymes,	efflux	pumps,	or	membrane	permeability).		While	this	has	shown	some	efficacy,	there	is	little	doubt	that	resistance	to	these	RMAs	will	emerge	(if	it	hasn’t	already,	as	seen	the	case	of	Clavulanic	Acid).	Furthermore,	bacteria	can	express	multiple	resistance	mechanisms,	so	even	if	one	mechanism	is	inhibited,	another	mechanism	could	just	be	up-regulated	or	expressed.	For	instance,	it	is	estimated	that	at	least	10%	of	resistance	in	MRSA	strains	is	due	to	efflux	pumps	alone16.		Therefore,	while	such	RMAs	offer	short-term	solutions,	not	to	undermine	their	value	clinically,	but	they	will	be	transient	in	the	fight	against	resistance.	A	new	class	of	RMAs	may	show	a	renewed	promise.	Instead	of	targeting	the	resistant	mechanisms	specifically,	or	the	product	of	gene	expression,	what	if	we	could	target	the	very	expression	of	resistant	mechanisms	(e.g.	resistance-conferring	genes)	(Figure	1.7)?	
Figure	1.7.	"Bacterial	Resistance	to	Antibiotics."	
Http://textbookofbacteriology.net.	N.p.,	n.d.	Web.	18	Feb.	
2016.	
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If	the	bacteria	cannot	express	the	resistance	mechanisms	or	up-regulate	production	of	such	mechanisms,	theoretically	we	could	cut	off	the	very	development	of	the	resistance	problem	to	begin	with.	Under	the	theory	that	resistance-conferring	genes	are	(physically)	close	to	one	another	on	the	bacterial	chromosome	(based	upon	plasmid	transference	of	multiple	resistant	genes	for	one);	it	is	reasonable	to	postulate	that	any	compound	affecting	this	region	of	the	chromosome	could	regulate	expression	of	several	resistance	mechanisms	(Figure	1.7).		As	an	example,	while	the	normal	response	of	bacteria	under	antibiotic	pressure	may	be	to	up-regulate	expression	of	β-lactamase,	the	RMA	would	antagonistically	prevent	this	increase.	If	expression	were	unable	to	increase,	then	our	ability	to	target	resistance	mechanisms	would	become	more	manageable.	For	instance,	in	the	case	of	the	β-lactamase	inhibitor	clavulanic	acid,	bacterial	up-regulation	of	β-lactamases	can	overcome	inhibition	(due	to	the	1:1	irreversible	binding	ratio).	If	β-lactamase	expression	could	not	up-regulated,	the	combination	of	β-lactams	and	β-lactamase	inhibitors,	such	as	clavulanic	acid,	could	remain	effective.		
1.5	Working	in	Biochemical	Space	While	this	all	may	sound	sensible	and	clever,	by	no	means	is	it	easy.	There	are	several	components	of	working	in	biochemical	space	that	are	worth	highlighting.	Firstly,	the	significance	of	mutation	and	specificity	should	not	be	underestimated.	To	illustrate	this	point	the	physiological	example	of	two	human	hormones,	vasopressin	and	oxytoxin	may	be	used.	These	two	nonapeptides	differ	only	by	two	amino	acids,	which	is	the	result	of	only	three	different	nucleotides22,23,	
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and	yet	they	have	comepletely	different	effects	in	the	body.	Vasopressin	primarily	helps	regulate	water	balance	and	blood	pressure,	while	oxytocin	stimulates	uterine	contractions.	Clearly	their	structures	are	very	deliberate	and	any	change	in	either	hormones’	amino	acid	sequence	(which	could	result	from	a	single	point	mutation)	could	result	in	dysfunction.	To	extend	this	example	to	the	development	of	RMAs,	only	the	slightest	alteration	in	RMA	structure	could	make	it	both	incredibly	effective	or	comepletely	futile;	thus	the	task	of	discovering	novel,	effective	RMAs	in	a	vast	chemical	space	is	comparable	to	(strategically)	finding	a	needle	in	a	haystack.	Likewise,	based	upon	the	significance	of	only	three	nucleotides	making	the	difference	between	these	two	human	hormones,	clearly	it	would	take	very	little	mutation	to	make	significant	alterations	(or	lead	to	resistance).	With	the	right	point	mutation(s),	theoretically	the	active	site	of	a	β-lactamase	(or	any	other	protein)	could	change	dramatically.	Also	it	is	worth	highlighting	some	points	on	protein	function	in	biochemical	space.	Biochemically,	protein	folding	into	tertiary	structures	is	incredibly	complicated	to	model	due	to	the	variety	of	interactions	that	occur	in	the	folding	process	as	a	result	of	different	charges,	structures,	and	electronegativity.	Even	if	we	know	the	amino	acid	sequence	for	a	given	protein	(which	is	possible	with	DNA	sequencing)	the	three	dimensional	nature	the	protein	takes	is	harder	to	fully	model.	The	active	sites	of	such	proteins	are	also	complicated	three-dimentional	pockets,	and	while	we	may	know	some	features	within	them,	only	slight	changes	to	the	RMA	chemical	structures	can	greatly	increase	binding	affinity	because	it	may	induce	a	better	fit	into	the	pocket	(as	would	apply	to	β-lactamase	inhibitors	for	instance).		
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Furthermore,	when	a	protein	binds	to	a	compound	or,	for	instance	DNA,	the	protein	often	undergoes	a	conformational	change.	This	is	even	harder	to	model.	Protein	binding	systems,	which	includes	the	system	of	DNA	expression,	therefore	are	highly	complicated	however	also	open	to	manipulation	in	a	variety	of	ways.	For	instance,	theoretically	a	compound	(e.g.	RMA)	could	alter	a	regulatory	protein	by	allosteric	binding	(binding	to	a	site	on	the	protein	other	than	the	active	site)	which	could	induce	a	conformational	change	resulting	in	an	unfuctional	active	site,	or	stabilize	the	repressor	protein’s	binding	to	DNA	(as	is	theorized	with	Of120),	resulting	in	reduced	expression.	In	essence,	the	systems	in	which	we	are	working	are	highly	varible,	sensitive,	and	complicated	to	model;	yet,	due	to	those	same	features,	open	to	manipulation,	so	RMA	development	is	a	perpetual	task	but	highly	hopeful.	
	
1.6	Wang	Lab	
1.6.1	Background	A	key	hypothesis	in	development	of	new	antimicrobials	in	Wang	lab	is	that	synthetic	structures,	as	compared	to	natural	compounds,	will	have	a	longer	effective	lifespan	before	resistance	develops	against	them.	The	theory	behind	this	lies	in	that	most	bacteria	already	have	resistance	genes	in	their	chromosomal	make-up15.	Under	this	theory,	if	bacteria	have	ancient	encoded	DNA	for	resistance	genes,	it	would	be	a	precondition	that	it	was	through	exposure	to	some	natural	compound(s)	(e.g.	antibiotics).	Therefore,	as	bacteria	have	not	yet	come	across	the	synthetic	compounds,	they	will	not	already	have	coordinated	resistance	genes	buried	
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somewhere	in	their	microbial	genome.	While	it	is	inevitable	that	resistance	genes,	even	against	synthetic	compounds,	will	develop	in	bacteria1,	it	will	be	more	time	consuming	to	develop	new	resistance	genes	than	express	genes	already	in	their	genetic	make	up.		A	catch	of	course	to	the	development	of	synthetic	compounds	that	will	be	effective	against	antimicrobials	is	that	the	vast	majority	of	compounds	existing	in	chemical	space	have	no	antimicrobial	activity;	as	was	realized	in	the	late	1990s	when	pharmaceutical	giant	GlaxoSmithKline	spent	$200	million	on	putting	a	library	of	500,000	synthetic	compounds	through	70	biochemical	screens,	only	to	yield	no	clinically	exploitable	compounds18.	Thus,	approaching	synthetic	drug	development	can	be	a	challenge.		Several	years	ago	a	polycyclic	indoline	library	was	synthesized	and	screened	by	Wang	lab.	This	library	was	bio-inspired	based	upon	the	principle	that	naturally	occurring	indole	alkaloids	have	a	wide	arrary	of	bioactivity,	the	majority	of	which	were	plant	secondary	metabolites.	For	instance,	melatonin	and	serotonin,	well	known	human	hormones	with	psychoactive	qualities,	have	indole-based	structures.	Indole-derivatives	have	a	major	role	in	many	areas	of	medical	pharmaceuticals	including	applications	as	anticancers,	vasodialators,	antihypertensives,	anti-HIVs,	antivirals,	β-blockers,	and	opioid	agonists	–	many	of	these	are	derivatives	of	naturally	occurring	parent	compounds19.	To	make	a	synthetic	library	similar	to	highly-active	natural	indoles	alkaloids,	Wang	lab	synthesized	a	library	of	polycyclic	indolines	(Figure	1.9);	the	basic	structural	difference	is	the	absence	of	a	double	bond	in	the	five-carbon	ring	of	the	latter	(Figure	1.8).	
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	 The	library	consisted	of	approximately	170	different	synthetic	indoline	compounds	and	26	unique	skeletal	structures,	a	comparatively	small	compound	library	compared	to	GlaxoSmithKline’s.	To	test	for	bioactivity,	the	library	was	screened	for	anticancer	
activity	(since	many	indoles	have	anticancer	properties)	and	antimicrobial	activity.	Several	compounds	were	hits,	showing	bioactivity	in	the	screens.	That	there	were	several	hits	supported	the	concept	that	a	successful	library	should	be	synthesized	with	some	strategic	methodology	in	terms	of	the	chemical	space	it	is	derived	from.		 The	indoline	library	was	further	screened	specifically	for	RMA	activity	with	MRSA	ATCC	BAA-44,	a	strain	resistant	to	a	variety	of	classes	of	antibiotics	including	β-lactams	and	tetracyclines,	and	S.	aureus	(VRSA)	NR-46421,	a	bacterial	strain	
Figure	1.9.	Podoll,	Jessica	D.,	et	al.	"Bio-inspired	synthesis	yields	a	tricyclic	indoline	that	
selectively	resensitizes	methicillin-resistant	Staphylococcus	aureus	(MRSA)	to	β-lactam	
antibiotics."	Proceedings	of	the	National	Academy	of	Sciences	110.39	(2013):	15573-15578.	
N
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Figure	1.8.	Natural	Indole	Structure	and	
Synthetic	Indoline	Structure.	
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specifically	resistant	to	vancomycin.	There	were	10	hits;	the	most	promising	of	these	hits	was	a	compound	known	as	Of1	(Figure	1.10).		Of1	was	further	analyzed	to	understand	its	mechanistic	function	in	re-sensitizing	resistant	S.	aureus	to	β-lactam	antibiotics.	It	was	shown	that	Of1	targeted	non-essential,	resistance-conferring	bacterial	genes20.	This	was	shown	through	gene	expression	studies	performed	by	Wang	lab	and	described	more	thoroughly	in	Dr.	Podoll’s	PhD	thesis,	but	is	worth	highlighting.	Essentially,	a	RT-qPCR	gene	expression	assay	was	performed	on	two	strains	of	bacteria,	one	which	expresses	a	common	β-lactamase	(blaZ),	and	the	other	both	β-lactamase	(BlaZ)	and	PBP2a	(MecA),	a	common	‘resistant’	variant	of	a	penicillin	binding	protein	that	weakly	binds	β-lactam	antibiotics20.	Each	was	grown	with	varying	amounts	of	amoxicillin	and	Of1	for	an	hour,	the	cells	were	lysed,	and	RNA	collected;	primers	for	BlaZ	and	mecA	were	then	used	to	find	the	transcript	levels	with	RT-qPCR	and	normalized	against	16S	rRNA	levels.	In	both	strains,	BlaZ	transcription	was	reduced	in	a	dose-dependent	manner	correlated	to	increasing	concentrations	of	Of1	(in	combination	with	a	constant	concentration	of	amoxicillin).	This	supported	a	previous	hypothesis	on	Of1’s	action	of	reducing	β-lactamase	expression,	however,	the	real	excitement	came	with	the	empirical	data	showing	that	PBP2a	(mecA)	transcription	was	also	reduced	in	a	similar	dose-dependent	manner.	While	the	exact	mechanism	of	action	is	still	unknown,	the	results	of	this	study	indicate,	“…that	Of1	targets	some	aspect	of	the	
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Figure	1.10.		
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bla/mec	induction	pathway	and	accordingly	reduces	transcription	of	the	resistance	determinants”20.	This	promising	discovery	suggests	that	it	is	an	entirely	new	class	of	resistance-modifying	agents.	While	there	have	been	discoveries	of	mechanism-targeting	resistance-modifying	agents,	such	as	β-lactamase	inhibitors,	the	targeting	of	and	foreseen	regulatory	ability	of	gene	expression	is	exciting	because	it	could	inhibit	a	variety	of	resistance	mechanisms,	as	oppose	to	just	one.			
1.6.2	YXL-166	Although	Of1	was	the	most	promising	of	the	compounds	screened,	there	were	9	other	“hits”.	The	second	most	promising	compound	from	this	screen	was	a	compound	called	“YXL-166”,	which	is	now	undergoing	further	analysis	and	is	the	compound	featured	in	this	study.	In	the	initial	screens,	YXL-166	showed	an	ability	to	potentiate	methicillin,	a	narrow	spectrum	β-lactam,	in	MRSA	BAA-44.	Tests	were	then	run	with	a	panel	of	antibiotics	and	YXL-166	showed	to	potentiate	a	variety	of	β-lactam	antibiotics	but	did	not	show	significant	potentiation	with	other	antibiotic	classes	(Table	1.1).							
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	Table	1.1	
	
MRSA	(BAA-44)	
Class	 		 Alone	
c166	
(20uM)	
		 Methicillin	 256	 8	
β-
la
ct
am
	 Amoxicillin/Amox-	Clavulanic	Acid	
Mix	 32/16	 32/2	
Ampicillin	 256	 128	
Cefazolin	(1g	cephalosporin)	 256	 8	
Meropenem	 32	 2	
Oxacillin	 64	 8	
Lipopeptide	 Daptomycin	 256	 256	
Fluoroquinolone	 Ciprofloxacin	 16	 4	
Lincosamide	 Clindamycin	 >256	 256	
Macrolide	 Erythromycin	 >256/128	 128/64	
Aminoglycoside	 Gentamycin	 256	 256	
Oxazolidonone	 Linezolid	 2	 NR	
Rifamycin	 Rifampicin	 2	 NR	
Aminoglycoside	 Streptomycin	 >256	 >256	
Polyketide	 Tetracycline	 32	 16/8	
Glycopeptide	 Vancomycin	 1	 NR	
	 	 	 	
	
NR	=	non-resistant,	so	no	MIC	can	be	taken		
1.6.3	SAR	Analysis	A	structure-activity	relationship	study	is	performed	to	fully	understand	which	parts	of	the	compound	are	most	crucial	to	the	compound’s	activity	and	if	any	modifications	can	be	made	to	discover	a	more	potent	lead	compound.	To	be	clear,	there	are	several	factors	that	must	be	accounted	for	in	the	potency	of	a	compound.	An	ideal	compound	has	the	qualities	of	being	effective	at	low	concentrations,	minimally	toxic	to	mammalian	cells,	and	versatile	in	the	strains	of	resistant	bacteria	and	a	specific	class	of	antibiotics	it	can	work	with.	Furthermore,	there	are	considerations	that	must	be	made	in	terms	of	the	end	goal	of	its	use	in	humans,	or	in	other	words	the	transition	from	in	vitro	to	in	vivo	testing	and	efficacy.	For	instance,	
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in	vivo,	high	water	solubility	and	hydrophilicity	(and	by	effect	polarity)	are	necessary	physiochemical	properties	for	the	RMA	to	be	effective	in	the	human	body.		
		Table	1.2	 	 	 	 	 BAA-44	entry	 compd	 R1	 GI50		(HeLa)	 Amox.Clav	a	 Cefazolin	a	1	 166	 Me	 20	 16	 8	2	 YG-I-71-1	 H	 28	 16	 8	3	 YXL-389	 Et	 30	 4	 2	4	 YG-517	 Propargyl	 17	 64	 64	
aAll	GI50	and	MRC	values	are	in	µg/mL.			 Modifications	were	first	made	on	the	indole	nitrogen.	The	initial	compound	(entry	1,	Table	1.2)	had	a	methyl	group	and	the	MRCs	for	cefazolin	and	amox/clav	(a	combination	of	amoxicillin	and	the	β-lactamase	inhibitor	clavulanic	acid),	were	8	
µg/mL	and	16	µg/mL,	respectively.	By	changing	the	group	to	an	ethyl	(entry	3,	Table	1.2),	the	MRC	decreased	four-fold	for	both	cefazolin	and	amox/clav	and	the	GI50	also	increased	slightly.	Exchanging	the	methyl	with	hydrogen	(entry	2,	Table	1.2)	kept	the	MRCs	the	same	and	adding	a	propargyl	(entry	4,	Table	1.2)	dramatically	increased	the	MRCs.				
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					Table	1.3	 	 	 	 	 	 	 BAA-44	entry	 compd	 R2	 R3	 R4	 GI50		(HeLa)	 Amox.Clav	a	 Cefazolin	a	1	 166	 Me	 H	 Me	 20	 16	 8	12	 YG-44-1	 H	 Me	 H	 22	 8	 4	13	 YG-46-1	 H	 H	 H	 30	 >64	 >64	14	 YG-55-1	 H	 Cl	 H	 57	 8	 4	
aAll	GI50	and	MRC	values	are	in	µg/mL.			Next,	modifications	were	made	on	the	phenyl	ring.	The	initial	compound	(entry	1,	Table	1.3)	had	a	methyl	on	C4	(R2)	and	C6	(R4)	of	indoline,	with	a	hydrogen	in	between	at	the	C5	(R3).	The	analogues	all	had	hydrogens	at	R2	and	R4,	and	then	had	either	methyl	(entry	12,	Table	1.3),	hydrogen	(entry	13,	Table	1.3),	or	chlorine	(entry	14,	Table	1.3)	at	R3.	The	hydrogen	at	R3	dramatically	reduced	RMA	activity,	while	the	methyl	and	chlorine	both	increased	RMA	activity	equally,	two-fold	for	cefazolin	and	four-fold	for	amox/clav.	However,	chlorine	was	better	overall	because	it	increased	the	GI50	by	nearly	200	percent.								
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					Table	1.4	 	 	 	 	 BAA-44	entry	 compd	 R5	 GI50		(HeLa)	 Amox.Clav	a	 Cefazolin	a	1	 166	 NCOOMe	 20	 16	 8	5	 YG-I-12-1	 NCOOEt	 >200	 4/8	 4	6	 YG-I-14-1	 NCOOBn	 >200	 64	 >64	7	 YG-59-1	 NTfa	 >200	 >64	 >64	8	 YG-58-2-1	 NAc	 15	 32	 64	9	 YG-I-13-1	 NSO2PhCl	 179	 >64	 >64	10	 YG-I-09-1	 N-Me	 25	 16	 16	11	 YG-I-16-1	 N-Et	 23	 32/>64	 16	17	 YG-I-90-1	 NCONHBn	 >200	 >64	 >64	18	 YG-I-95-1	 NCOOtBu	 159	 4	 4	21	 YG-I-109-1	 NSuc	 >200	 >64	 >64	22	 YG-98-1	 NCON6NMe	 >200	 >64	 >64	23	 YG-I-115-1	 NCONCOCCl3	 19	 64	 64	24	 YG-I-99-1	 NGuaBoc2	 11	 64	 64	25	 YG-I-116-1	 NGua	 19	 32	 64	
aAll	GI50	and	MRC	values	are	in	µg/mL.			 Next,	a	variety	of	modifications	were	made	on	the	second	nitrogen,	most	of	which	did	not	improve	RMA	activity.	The	general	trend	pointed	to	the	importance	of	the	carboxyl	group	skeleton	remaining	on	the	second	nitrogen,	although	it	could	withstand	slight	modifications	on	the	distal	end,	which	improved	RMA	activity.	The	initial	compound	(entry	1,	Table	1.4)	had	a	methyl	group	coming	off	the	carboxyl	group.	Enlarging	the	methyl	to	an	ethyl	(entry	5,	Table	1.4)	or	tert-butyl	(entry	18,	Table	1.4)	group	improved	RMA	activity	two-fold	for	cefazolin	and	four-fold	for	amox/clav.	Also	both	dramatically	improved	mammalian	cell	toxicity,	the	ethyl	
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(entry	5,	Table	1.4)	to	levels	above	the	testing	range	(>200),	suggesting	nominal	toxicity	to	human	cells.		
		Table	1.5	 	 	 	 	 	 BAA-44	entry	 compd	 R6	 R7	 GI50		(HeLa)	 Amox.Clav	a	 Cefazolin	a	1	 166	 CH2CH2	 Closed	Ring	 20	 16	 8	19	 YG-I-101-1	 CH2	 Closed	Ring	 40	 8	 4	20	 YG-I-108-2	 CH2CH2	 Open	Ring	 >200	 >64	 >64	
aAll	GI50	and	MRC	values	are	in	µg/mL.			 Analogs	with	ring	modifications	including	ring	openings	and	decreasing	ring	size	were	made.	Opening	the	ring	(entry	20,	Table	1.5),	although	improving	the	GI50	to	nominal	toxicity	levels,	dramatically	increased	the	MRCs	(>64	µg/mL),	so	the	ring	structure	was	deemed	an	important	part	of	the	compound.	The	initial	ring	was	seven-membered	(entry	1,	Table	1.5);	a	change	to	a	six-member	ring	(entry	19,	Table	1.5)	improved	RMA	activity	two-fold	and	slightly	increased	GI50.		
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						Table	1.6	 	 	 	 	 	 	 	 	 BAA-44	entry	 compd	 R1	 R2	 R3	 R4	 R5	 R6	 GI50		(HeLa)	 Amox.Clav	a	 Cefazolin	a	1	 166	 Me	 Me	 H	 Me	 NCOOMe	 CH2CH2	 20	 16	 8	16	 YG-51-1-1	 COOMe	 Me	 H	 Me	 N-H	 CH2CH2	 58	 64	 64	26	 YG-I-258-1	 Me	 H	 Me	 H	 N-Me	 CH2	 24	 64	 64	27	 YG-I-261-1	 Me	 H	 Me	 H	 NCOOEt	 CH2	 43	 32	 32	28	 YG-I-263-1	 Me	 H	 Cl	 H	 N-Me	 CH2	 21	 64	 64	29	 YG-I-262-1	 Me	 H	 Cl	 H	 NCOOEt	 CH2	 41	 8	 8	30	 YG-I-254-1	 Me	 H	 Me	 H	 NCOOMe	 CH2	 15	 16	 16	
aAll	GI50	and	MRC	values	are	in	µg/mL.			 After	each	part	of	the	structure	was	analyzed	for	activity	the	most	promising	qualities	were	combine	to	create	a	“super”	analogue.	R1	remained	the	mostly	the	same	as	in	the	initial	compound	(entry	1,	Table	1.6)	as	a	methyl.	R2,	R3,	and	R4	which	was	initially	methyl,	hydrogen,	methyl	(entry	1,	Table	1.6)	was	exchanged	for	a	hydrogen,	methyl,	hydrogen	(entry	12,	Table	1.6)	or	hydrogen,	chlorine,	hydrogen	(entry	14,	Table	1.6)	based	off	of	both	(entry	12,	Table	1.3)	and	(entry	14,	Table	1.3)	equally	reducing	the	MRCs	two-fold	for	both	amox/clav	and	cefazolin.	R5	was	initially	NOOMe	(entry	1,	Table	1.6),	and	was	exchanged	for	several	substitute	varieties,	including	NCOOEt	(entry	5,	Table	1.2)	which	had	reduced	the	MRC	by	at	least	two-fold	for	both	amox/clav	and	cefazolin.	Although	R5	also	had	good	results	with	NOOtBu	(entry	18,	Table	1.4),	this	large	group	is	very	hydrophobic	so	would	likely	not	work	well	in	vivo,	thus	was	not	continued	into	the	final	analogue	
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structures.		R6	which	initially	was	a	7-member	ring	(entry	1,	Table	1.5)	was	replaced	mostly	with	a	6-member	ring	(entry	19,	Table	1.5)	as	it	had	reduced	the	MRC	two-fold	for	both	amox/clav	and	cefazolin.		Interestingly,	none	of	these	analogues	had	superior	activity	to	some	of	the	earlier	analogues	in	the	study.	Ultimately	the	best	analogue	to	move	forward	with	was	determined	to	be	(entry	5,	Table	1.4),	or	YG-I-12-1	(Figure	1.11).	While	other	analogues	also	had	MRCs	for	both	amox/clav	and	cefazolin	of	4	µg/mL,	(entry	5,	Table	1.4)	also	had	a	GI50	of	>200,	indicating	that	it	was	nominally	toxic	to	human	cells.			
1.6.4	Future	Directions	This	process	of	compound	development	is	ongoing,	and	a	new	set	of	166	analogues	are	currently	undergoing	testing.	It	is	important	to	recognize	that	in	this	methidological,	yet	exploratory	form	of	research	it	is	common	to	continue	to	develop	the	project	over	extended	period	of	time.	For	instance,	even	Of1,	the	landmark	RMA	compound	developed	by	Wang	lab	in	2013,	is	still	undergoing	further	experimental	modifications.	This	is	because	slight	alterations	can	make	a	world	of	a	difference	due	to	the	complexity	of	biochemical	space	and	the	interactions	within	it.	Nonetheless,	we	do	plan	on	significantly	moving	forward	with	several	compounds	in	the	coming	year.	Specifically,	there	will	be	further	testing	of	several	
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Figure	1.11	
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more	(new)	YXL-166	analoges	with	several	strains	of	multi-drug	resistant	MRSA	in	the	coming	month.	We	anticipate	discovering	a	more	potent	lead	compound	based	upon	subsequent	modifications	following	the	SAR	analysis	(above).		Time-kill	trials	will	be	run	with	Of1	and	the	lead	compound(s)	derived	from	YXL-166.	And	excitingly,	we	are	in	the	process	of	writing	a	proposal	for	mice	trials,	which	we	anticipate	will	comense	this	year.		
1.6.6.	Materials	and	Methods	BAA-44	was	scratched	on	tripticase	soy	broth	(TSB)	agar	plates	and	incubated	at	37°C	overnight.	Individual	colonies	were	then	selected	and	grown	in	Mueller	Hinton	Broth	(MHB)	for	approximately	six	hours	at	37°C	in	a	shaker	at	220	RPM.	Using	a	spectrophotometer,	the	optical	density	was	then	measured	at	a	wavelength	of	600	nm	to	determine	the	absorbance	of	the	sample	(OD600),	which	correlates	to	cell	density;	increased	incubation	time	exponentially	increases	the	number	of	cells	in	the	sample	until	saturation.	For	our	purposes,	an	OD	of	0.200-0.400	was	ideal	because	it	suggests	the	bacteria	are	in	a	healthy	prolific	state	(as	oppose	to	saturation	where	they	would	be	in	a	starving	state).	The	OD	does	not	provide	an	absolute	value	for	cells/mL,	so	a	standard	curve	must	be	created	to	appropriately	quantify	cell	density.	A	standard	curve	was	created	by	using	10x	serial	dilutions	of	a	sample	starting	at	an	OD	of	0.100.	5	μl	of	each	sample	was	plated	on	33	cm2	agar	plates,	spread	with	5	glass	beads	each.	Each	diluted	sample’s	OD	was	also	measured	and	recorded.	After	overnight	incubation	at	37°C,	individual	colonies,	or	Colony-
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Forming	Units	(CFU)	were	counted.	It	is	assumed	that	each	cell	will	give	rise	to	a	single	colony,	thus	cell	count	can	be	determined	as	equivalent	to	CFUs.	When	a	preliminary	dilution	range	was	determined	as	diluted	enough	to	count	individual	cells	(some	dilutions	resulted	in	too	high	of	a	cell	concentration	to	count,	appearing	as	“lawns”	on	the	plates),	this	range	was	repeated	in	triplicate	to	determine	a	standard	error.	Using	Microsoft	Excel,	a	standard	curve	was	calculated	(Figure	1.12).	
The	MIC,	or	minimum	inhibitory	concentration,	of	BAA-44	with	cefazolin	and	amox/clav,	respectively,	was	measured	using	a	standard	microdilution	method.	Each	antibiotic	was	serial	diluted	two	fold	from	256	-	2	µg/mL	for	Cefazolin	and	64	-	0.5	µg/mL	for	Amox/clav,	with	40	µl	in	each	well.	Bacteria	was	diluted	in	MHB	to	an	OD	of	0.005	and	10µl	of	was	added	to	each	well	(calculated	for	a	final	bacteria	OD	of	0.001	based	on	a	5:1	dilution);	the	plates	were	then	incubated	in	a	shaker	at	37°C	
Figure	1.12.	Standard	Curve	of	BAA-44	to	convert	OD600	to	CFU.	
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for	18	hours.	Following	the	18-hour	growth	period,	the	wells	were	examined	by	holding	them	up	to	a	light;	clear	wells	indicated	inhibited	bacterial	growth	and	cloudy	were	not	inhibited.	This	was	repeated	in	triplicate.	The	lowest	concentration	of	antibiotic	where	growth	was	inhibited,	as	indicated	by	a	clear	well,	was	the	MIC.	The	BAA-44	MICs	for	cefazolin	and	amox/clav,	respectively,	were	>256	µg/mL	and	32	µg/mL.	Similar	MICs	were	also	performed	with	each	synthesized	compound	(RMA)	with	two-fold	serial	dilutions	from	64-0.5	µg/mL	and	bacteria.	All	MICs	were	>64	
µg/mL,	indicating	that	the	compounds	had	no	inhibitory	effects	on	their	own.		Next,	the	MRC,	or	minimum	re-sensitizing	concentration,	was	measured;	this	was	to	assess	the	compound’s	bioactivity	in	combination	with	the	antibiotic	on	the	bacteria.		Compounds	maintained	the	same	serial	dilutions	as	before	(64-0.5	
µg/mL),	while	the	concentration	of	each	antibiotic	was	held	constant	at	8	µg/mL	for	cefazolin	and	4	µg/mL	for	amox/clav.	Similarly	as	before,	bacteria	were	added	so	the	final	OD	of	bacteria	added	to	each	well	was	0.001.	The	plates	were	then	incubated	in	a	shaker	at	37°C	for	18	hours.	Each	assay	was	performed	in	triplicate	to	confirm	the	results.	Throughout	the	MRCs,	Of1	was	used	as	a	control.		
1.6.6	Time-kill	Experiments	Time-kill	experiments	are	used	to	monitor	the	growth	of	bacteria	under	various	conditions;	in	our	case,	the	experiment	is	used	to	monitor	the	activity	of	RMAs	and	antimicrobial	activity.	It	helps	with	analysis	by	providing	information	such	as	“the	rate	of	kill,	time	from	addition	of	antibiotic	to	initiation	of	killing,	
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and…degree	of	killing	observed”21.	By	constructing	a	best-fit	curve,	we	can	also	see	the	degree	and	process	of	synergism	between	the	RMA	and	antibiotic,	as	compared	to	the	antibiotic	alone	by	comparing	the	curves.	This	testing	is	still	in	progress,	but	has	been	run	with	BAA-44	and	different	concentrations	of	amox/clav	(Figure	1.13).	
	
Figure	1.13.	BAA44	growth	over	24	hours	with	no	antibiotics,	½x,	1x,	2x,	and	4x	MIC	of	amox/clav.		Aliquots	of	500	mL	Mueller-Hinton	II	broth	cation	adjusted	(CAMHB)	were	put	in	sterile	culture	tubes.	Amox/clav	was	added	to	equal	[0,	8,	16,	32,	and	64]	
µg/mL,	which	correlates	to	no	antibiotics,	½x,	1x,	2x,	and	4x	the	MIC	of	Amox/clav,	respectively,	with	BAA44	(16	µg/mL).	A	primary	culture	that	was	grown	overnight	until	near-saturation	(12hr)	was	sub-cultured	to	an	OD	of	0.1	in	each	culture	tube.		Initial	OD	was	measured	for	each	culture,	and	the	cultures	were	placed	in	a	shaker	at	37°C.	The	OD	was	measured	again	at	2,	6,	and	24	hours.	Using	the	standard	curve	previously	calculated,	OD	was	converted	to	CFUs	and	growth	was	plotted.	Growth	was	markedly	inhibited	at	an	MIC	of	2x	and	4x	Amox/clav.	
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CHAPTER	2:	Community-Acquired	Resistance	and	FDA	Regulations		
2.1	Introduction	Today,	in	the	United	States	80%	of	all	antibiotics	are	used	in	food-producing	animals12,	and	there	is	a	wide	consensus	that	a	major	cause	of	human	community-acquired	resistance	to	antibiotics	is	due	to	antibiotic	use	in	food-producing	animals.	While	most	deaths	due	to	antibiotics	resistance	occur	from	clinically-acquired	resistance,	a	result	of	“unnatural”	selective	pressure,	“most	antibiotic-resistant	infections	happen	in	the	general	community”1.	This	is	the	result,	foremost,	of	extraordinarily	large	quantities	of	antibiotics	being	used	sub-therapeutically	in	the	food	chain,	especially	in	livestock.	This	problem	of	misusing	and	overusing	antibiotics	in	livestock	has	long	awaited	governmental	regulation;	recently	FDA	released	the	much-anticipated	regulatory	changes.	In	December	2013	FDA	asked	for	sponsors	(e.g.	the	pharmaceutical	companies	manufacturing	the	antibiotics)	to	voluntarily	commit	to	submitting	medically	important	antibiotics	for	reclassification	and	relabeling	within	three	months.	If	sponsors	did	not	voluntarily	submit	the	antibiotics	requested,	FDA	indicated	that	legal	action	would	be	taken	(under	the	FD&C	Acti)	to	assure	that	any	medically	important	antibiotics	were	re-regulated.	The	vast	majority	of	sponsors	voluntarily	submitted	the	paperwork	for	relabeling	and	reclassifying	to	FDA.		However,	the	FDA	strategy	of	re-regulating	antibiotic	use	will	not	succeed	in	solving	the	major	problem	of	antibiotic	misuse	in	food	producing	animals.	Not	only																																																									i	The	FD&C	Act,	or	Federal	Food,	Drug,	and	Cosmetic	Act,	is	a	set	of	laws	that	allows	the	Food	and	Drug	Administration	(FDA)	to	regulate	food	and	drugs	in	the	United	States.	It	was	passed	by	congress	in	1938	and	is	what	gives	FDA	their	authority.	
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did	their	strategy	contain	major	loopholes	to	begin	with,	but	as	it	rolls	out,	it	is	clear	that	vital	components	of	the	planned	re-regulation	have	failed	to	be	executed,	thus	is	largely	barren	of	any	significant	resolutions.		
2.	2	The	Mechanics	of	Community-Acquired	Antibiotic	Resistance	Because	microscopic	bacteria	are	everywhere,	the	process	of	resistance	can	build	up	in	animals,	plants,	and	humans2.	As	humans	eat	animal	meat	that	already	has	developed	resistant	bacteria	(which	has	been	encouraged	through	feeding	the	animal	subtheraputic	doses	of	antibiotics),	the	pathogenic	bacteria	travels	via	the	meat	into	our	gut.	In	the	human	gut	there	is	a	flora	of	hundreds	of	kinds	of	“good”	bacteria	that	help	break	down	the	meat	and	help	our	bodies	absorb	nutrients.	During	this	process	the	“good”	human	bacteria	meet	the	pathogenic	bacteria	(in	the	meat)	and	become	infected	with	the	same	resistance	mechanisms.	When	a	resistance	mechanism	has	been	introduced	and	spread	into	the	flora	of	human	gut	bacteria,	it	is	unlikely	that	the	human	would	take	any	notice.	The	generalized	accumulation	of	resistance	bacteria	will	propagate	in	the	general	population	because	people	serve	as	both	reservoirs	and	vectors	for	bacterial	populations.	Therefore,	the	resistance	bacteria	will	proliferate	and	be	excreted	through	urine	in	feces	back	into	the	communal	environment.	Only	later	when	a	human	becomes	ill	with	a	(unrelated)	bacterial	infection	and	seeks	treatment	would	it	become	apparent	that	prescribed	antibiotics	won’t	work	for	that	patient	due	to	unknown	resistance.	This	can	be	seen	by	penicillin’s	efficacy	being	virtually	eradicated	today.		
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2.3	A	Short	History:	Legal	Regulations	of	Antibiotic	Use	in	Livestock	Fifty	years	ago,	farmers	were	concerned	with	how	to	supply	enough	food	to	sustain	a	booming	population.	It	was	the	golden	age	of	antibiotic	discovery,	and	a	time	that	revolutionized	medicine.	While	initially	used	to	treat	and	prevent	illnesses	in	animals,	it	was	quickly	discovered	that	antibiotics	also	helped	the	animals	grow	bigger	and	more	quickly	(producing	more	food	for	human	consumption);	it	seemed	to	be	a	godsend.	Additionally	antibiotics	were	used	in	humans.	What	could	be	the	danger?	Because	antibiotics	were	so	promising,	in	the	1960s	the	Food	and	Drug	Administration	(FDA)	approved	classification	and	labeling	for	many	antibiotics	as	over-the-counter	drugs	for	growth	promotion	purposes	(“production	uses”)	in	livestock.		Nearly	ten	years	later,	the	1969	“Swann	Report”	came	out	of	the	United	Kingdom	stating:	“There	is	ample	and	incontrovertible	evidence	to	show	that	man…commonly	ingest[s]	[gut]	bacteria	of	animal	origin,”	and	“It	is	clear	that	there	has	been	a	dramatic	increase	over	the	years	in	the	numbers	of	stains	of	[gut]	bacteria	of	animal	origin	which	shows	resistance	to	one	or	more	antibiotics…This	resistance	has	resulted	from	the	use	of	antibiotics	for	growth	promotion	and	other	purposes	in	livestock.”3.	Following	this	report,	FDA	began	researching	more	into	the	issue	and	in	1977	FDA	expressed	concerns	over	the	use	of	antibiotics	in	livestock.	FDA	proposed	to	withdraw	two	of	the	most	vital	classes	of	antibiotics,	penicillins	and	tetracyclines,	from	subtherapeutic	uses	in	livestock.	However,	by	this	time,	antibiotics	in	livestock	had	become	an	essential	industry	standard	for	farming	and	was	highly	profitable	for	the	pharmaceutical	industry.		FDA	met	much	resistance	
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from	Congress	to	make	any	legal	changes	that	would	diminish	the	use	of	antibiotics	in	food-producing	animals.	Over	the	following	twenty	years,	research	flooded	out	from	all	over	the	world	linking	antibiotic	use	in	animals	to	human	resistance.	Agencies	far	and	wide	looked	into	the	issue,	including	the	World	Health	Organization	(WHO),	the	World	Organization	for	Animal	Health	(OIE),	the	Food	and	Agriculture	Organization	of	the	United	Nations	(FAO),	and	the	Institute	of	Medicine	(IOM)	to	name	a	few.	In	2003	a	joint	panel	of	experts	from	FAO,	OIE,	and	WHO	convened	and	agreed	that	there	was	increased	human	resistance	due	to	“non-human	usage	of	antimicrobials”;	the	subtherapeutic	use	of	antimicrobials	“increased	the	occurrence	of	resistant	bacteria”;	the	foodborne	route	was	a	major	“pathway	for	resistant	bacteria	and	resistant	genes”;	and	“the	consequences…are	particularly	severe	when	[the	resistance	is	to	antimicrobials	that	are]	critically	important	in	humans”2.			As	the	evidence	grew,	the	topic	was	passed	between	governmental	agencies	in	the	United	States.	In	2004	the	United	States	Government	Accountability	Office	(GAO)	confirmed	that	“antibiotic-resistant	bacteria	have	been	transferred	from	animals	to	humans”4,5	and	“this	transference	poses	significant	risks	to	human	health.”	The	Department	of	Health	and	Human	Services	(HHS)	agreed	saying,	“we	believe	that	there	is	a	preponderance	of	evidence	that	the	use	of	antimicrobials	in	food-producing	animals	has	adverse	human	consequences…There	is	little	evidence	to	the	contrary.”	5.	All	regulatory	governmental	bodies	looking	into	the	issue	agreed	that	antibiotic	misuse	in	food-producing	animals	is	a	major	threat	to	human	health.	
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However,	as	antibiotic	trade	is	a	multi-billion	dollar	industry,	industrial	giants	in	the	pharmaceutical	and	farming	industries	heavily	opposed	any	changes.	Congress	refused	to	acknowledge	research	linking	antibiotic	resistance	in	humans	to	antibiotic	use	in	food-producing	animals	as	significant5	and	has	been	a	major	impediment	to	any	potential	solution,	having	thrown	out	twelve		
Figure	2.1.	"Center	for	Disease	Dynamics,	Economics	&	Policy	(CDDEP)."	U.S.	Congressional	
Legislation	Relating	to	Antibiotic	Use,	2004-2014.	N.p.,	n.d.	Web.	21	Feb.	2016.	
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proposed	bills	addressing	the	issue	over	the	last	ten	years6	(Figure	2.1).	As	a	result,	and	with	encouragement	of	the	GAO,	WHO,	and	other	major	agencies	around	the	world,	it	falls	to	FDA	to	address	the	issue.		From	a	legal	standpoint,	it	is	within	FDA’s	power	to	ban	the	use	of	previously-approved	drugs	if	the	drugs	later	are	shown	to	risk	human	health	through	the	FD&C	Act.	However,	in	that	scenario,	FDA	must	also	prove	that	the	drug	use	is	harming	humans.	Since	there	are	many	types	of	antibiotics	and	combination	therapies	being	produced,	this	task	would	be	particularly	tedious,	time	consuming,	and	difficult.	Additionally,	there	are	other	factors	weighing	into	the	issue	of	regulation.	Notably,	animal	rights;	sick	animals	should	be	allowed	treatment.	And	of	course,	with	antibiotics	reaching	14.6	million	kilograms	sold	and	distributed	to	farms	in	2012	alone7,	there	is	a	clear	point	of	contention	economically	from	vested	industries:	a	battle	not	for	the	faint	at	heart.	Nonetheless,	FDA	proposed	a	plan.		
2.4	FDA’s	Plan	for	the	Re-regulation	of	Antibiotic	Use	in	Livestock	Starting	in	2003,	FDA	ranked	each	antibiotic	as	medically	important	(to	human	health)	or	not.	This	ranking	was	based	upon	the	probability	of	transference	of	resistant	bacteria	from	animal	to	human,	and	the	subsequent	consequences	if	a	human	were	to	be	exposed	to	resistant	bacteria8.	FDA’s	plan	proceeded	based	around	reclassifying	and	relabeling	‘medically	important’	antibiotics.	After	reclassification,	antibiotics	currently	available	over-the-counter	(OTC),	or	without	a	prescription,	will	require	a	prescription	(Rx)	from	a	veterinarian.	This	will	limit	access	to	antibiotics.	In	relabeling,	“subtherapeutic”	or	“nontherapeutic”	labeling	
	 45	
indications	(e.g.	“production	uses”)5	will	be	removed.	Production	uses	include	helping	with	feed	efficiency	and	weight	gain.	Since	medicated	feed	(including	water)	accounts	for	94%	of	antibiotic	administration	in	livestock7	and	can	only	be	administered	based	on	its	labeled	uses,	relabeling	would	essentially	illegalize	large-scale	distribution	of	medically	important	antibiotics	to	livestock.			Since	FDA’s	request	from	sponsors	for	the	‘voluntary’	submission	of	medically	important	antibiotics	for	reclassification,	FDA	has	been	re-evaluating	and	re-labeling	previously	approved	antibiotics	under	these	new	guidelines.	The	question	then	becomes:	are	these	new	guidelines	sufficient?		
2.4.1	Labeling:	From	Clearly	Wrong	to	Vaguely	Obscure	According	to	FDA,	the	purpose	of	relabeling	medically	importantii	antibiotics	is	to	eliminate	production	uses	such	as	“increased	rate	of	weight	gain”	and	“improved	feed	efficiency”9.	As	it	is	illegal	to	distribute	antibiotics	for	reasons	not	explicit	on	the	label9,	this	would	outlaw	using	antibiotics	for	said	‘production	uses’.	Some	of	the	relabeled	antibiotics	include	‘medically	important’	tetracyclines	and	sulfas,	which	respectively	account	for	41%	and	3%	of	the	antibiotics	used	in	livestock7.	The	highest	levels	of	antibiotic	resistance	in	retail	livestock	(based	on	a	poultry	study)	are	also	tied	to	these	two	antibiotics:	65%	containing	bacteria	resistant	to	tetracyclines	and	45%	resistant	to	sulfas10.	
																																																								ii	Medically	important	to	human	health;	this	ranking	was	based	upon	the	probability	of	transference	of	resistant	bacteria	from	animal	to	human,	and	the	subsequent	consequences	if	a	human	were	to	be	exposed	to	resistant	bacteria8.	
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Chlortetracycline	(a	tetracycline)	is	classified	by	FDA	as	“highly	important”	to	human	health,	meaning	it	is	the	“sole	therapy	or	one	of	a	few	alternatives	to	treat	[typhus	and	anthrax]”8.	Sulfamethazine	(a	sulfa)	is	classified	as	“critically	important”,	meaning	it	is	(1)	an	antimicrobial	used	to	treat	food-borne	diseases,	(2)	the	“sole	therapy	or	one	of	a	few	alternatives	to	treat	serious	human	disease”	(in	this	case	pneumocystis	pneumonia),	and	(3)	an	antibiotic	that	is	used	to	treat	subsequent	diseases	caused	by	food-borne	pathogens	(such	as	neonatal	meningitis)8.		Clearly,	these	two	classes	of	drugs	are	highly	important	in	human	health	and	are	already	at	dangerous	levels	of	resistance	in	livestock.	In	an	excerpt	from	the	newly	revised	and	approved	labeling	for	combination	therapy	drug	‘558.140	chlortetracycline	and	sulfamethazine’	(for	cattle	and	pigs),	there	are	clear	production	use	indications	including,	“aid[s]	
in	the	maintenance	of	weight	gains”	(Figure	2.2).	While	in	
(d)	Conditions	of	use-	(1)	Cattle.	It	is	used	in	feed	for	beef	cattle	as	follows:	(i)	Amount.	350	milligram	per	head	per	day	each,	chlortetracycline	and	sulfamethazine	(ii)	Indications	for	use.	Aid	in	the	
maintenance	of	weight	gains	in	the	presence	of	respiratory	disease	such	as	shipping	fever.	(iii)	Limitations.	Feed	28	days;	withdraw	7	day	prior	to	slaughter…	(2)	Swine.	It	is	used	in	swine	feed	as	follows:	(i)	Amount.	100g/ton	each,	chlortetracycline	and	sulfamethazine	(ii)	Indications	for	use.	For	reduction	of	the	incidence	of	cervical	abscesses;	treatment	of	bacterial	swine	enteritis..;	prevention	of	these	
diseases	during	times	of	stress;	and	the	maintenance	of	weight	gains	in	the	presence	of	atrophic	rhinitis.		
Figure2.2.	An	excerpt	from	new	label	for	558.140	
Chlorotetracycline	and	sulfamethazine.	Food	and	Drug	
Administration,	HHS.	"New	Animal	Drugs	for	Use	in	Animal	
Feeds;	Chlortetracycline	and	Sulfamethazine;	
Chlortetracycline;	Procaine	Penicillin;	and	Sulfamethazine;”	
Federal	Register	79.127	(2014):	37622.	
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theory	production	purposes	such	as	“increased	rate	of	weight	gain”	and		“improved	feed	efficiency”9	were	supposed	to	be	removed	in	FDA’s	plan,	in	fact	they’ve	merely	been	relocated	under	conditional	situations	such	as	“times	of	stress”	(Figure	2.2).	Vague	conditions	are	open	to	interpretation	and	ultimately	to	abuse.	For	instance,	many	pigs	(swine)	are	raised	in	tight	quarters	that	prevent	movement;	it	would	be	reasonable	to	assume	that	they	are	constantly	stressed.	Under	this	new	labeling	it	would	be	reasonable	to	constantly	prescribe	pigs	a	daily	regiment	of	chlorotetracycline	and	sulfamethazine	because	“times	of	stress”	can	be	considered	likely	all	of	the	time.	In	effect,	the	labeling	has	not	remotely	changed	the	legality	of	constantly	distributing	medically	important	antibiotics	to	pigs.		Furthermore,	the	new	labeling	begs	the	question:	why	would	an	antibiotic	be	prescribed	to	“aid	in	the	maintenance	of	weight	gain	in	the	presence	of	[a]	disease”	(Figure	2.2)	as	opposed	to	being	prescribed	to	treat	the	disease	itself?	If	the	antibiotic	is	not	being	prescribed	to	treat	the	disease,	then	it	is	being	prescribed	to	promote	weight	gain	and/or	feed	efficiency,	which	is	exactly	what	FDA	was	suppose	to	be	removing	from	the	labeling	to	begin	with.	The	labeling	“changes”	are	more	of	a	rearrangement	of	words,	and	still	permit	production	uses	such	as	increasing	the	weight	of	livestock.		
2.4.2	A	Loophole:	Veterinary	Oversight	and	Judicious	Use	The	major	issue	in	FDA’s	plan	lies	in	their	concept	of	veterinary	oversight	and	judicious	use.	Switching	antibiotics	from	over-the-counter	(OTC)	to	prescription	(Rx)	was	designed	to	restrict	antibiotic	use	because	a	licensed	veterinarian	would	
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have	to	prescribe	the	antibiotics.	According	to	FDA	“judicious	use	involves	accurately	identifying	a	bacterial	disease	that	is	present	or	likely	to	be	present…”9.	By	“likely	to	be	present”	FDA	is	referring	to	preventative	medicine,	which	leaves	much	open	to	interpretation	given	that	the	conditions	the	majority	of	food-producing	animals	are	raised	in	are	also	ideal	spawning	grounds	for	bacterial	diseases.			FDA	says	there	are	important	factors	for	veterinarians	to	consider	in	the	case	of	prevention,	such	as	“no	reasonable	alternatives	for	intervention	exist”	and	factors	that	are	known	to	“increase	the	susceptibility	of	bacterial	disease,	including	environmental	factors	(such	as	temperature	extremes	and	inadequate	ventilation)…and	other	factors	(such	as	stress…).”9.		In	essence	then,	if	a	veterinarian	could	come	up	with	a	reasonable	alternative	intervention,	then	prescribing	preventative	antibiotics	would	be	injudicious.	A	layperson	might	come	up	with	the	reasonable	alternative	of	removing	the	animals	from	the	stressful	conditions	to	more	humane	conditions	that	are	less	susceptible	to	bacterial	disease,	but	would	the	veterinarian?	Perhaps	not,	depending	on	the	moral	and	ethical	beliefs	of	the	veterinarian.	A	veterinarian	could	also	prescribe	preventative	antibiotics		“…based	on	the	client’s	production	practices	and	herd	health	history”9.	This	FDA	guideline	alone	leaves	a	huge	loophole	for	veterinarians	to	‘judiciously’	prescribe	antibiotics.	Essentially	any	poor	‘production	practices,’	such	as	dirty	and	inhumane	conditions,	would	immediately	qualify	the	entire	herd	to	be	prescribed	“preventative”	antibiotics	for	the	length	of	those	conditions	remaining	unchanged.	To	some	extent	
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it	even	encourages	production	practices	to	remain	poor,	because	it	gives	producers	a	way	to	still	use	antibiotics	that	otherwise	would	not	be	permitted	if	conditions	improved.	To	note,	the	“preventative	antibiotics”	are	no	different	than	previously	administered	antibiotics	for	growth	purposes.	The	same	antibiotics	would	still	be	administered	in	feed	on	a	regular	bases,	and	thus	no	changes	are	actually	necessary	except	that	the	job	market	is	opening	up	for	unethical	veterinarians.		
2.5	Conclusion:	The	Danger	Lies	Dormant	The	danger	in	antibiotic	resistance	is	that	most	people	will	have	no	idea	that	they	are	resistant	until	they	are	ill	and	in	need	of	antibiotics.	An	apparently	healthy	child	could	scrape	his	knee	on	a	rusty	piece	of	playground	equipment	and	the	doctors	may	find	themselves	battling	to	save	the	child’s	life	from	a	minor	wound.	Because	there	is	a	degree	of	separation	between	the	pathogenic	(resistant)	bacteria	infecting	humans	and	the	consequences	of	antibiotic	resistance	becoming	apparent	(dependent	on	a	human	contracting	an	illness),	it’s	difficult	to	perceive	the	scope	of	this	problem	in	our	daily	lives.	And	in	truth,	we	shouldn’t	have	to.	Our	government	established	FDA	with	a	specialized	role	to	“protect	and	promote	[our]	health.”11	(www.fda.gov).	Not	only	is	FDA	being	negligent	in	their	duties	to	protect	the	American	people,	but	FDA	is	further	taking	advantage	of	the	trust	the	American	people	put	into	FDA.			 		
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Summary	and	Conclusion	Strides	in	new	antimicrobial	drug	development	largely	revolve	around	making	old	antibiotics	usable	again;	this	is	due	to	economic	advantages	and	the	low	feasibility	of	developing	novel	antibiotics.	Resistance-Modifying	Agents	(RMAs)	act	to	re-sensitize	resistant	bacteria	to	antibiotics	through	a	variety	of	mechanisms,	although	currently	most	target	bacterial	resistance	mechanisms	themselves,	such	as	β	-lactamases.	Foreseeably,	while	these	compounds	have	shown	efficacy	and	certainly	are	of	value	in	the	present	crisis,	it	is	a	short-term	solution	in	light	of	the	evidently	rapid	and	dynamic	capability	of	bacteria	to	respond	evolutionarily.	Nonetheless,	a	new	class	of	RMAs,	currently	being	researched	and	developed	at	Wang	lab,	hope	to	extend	the	lifespan	of	RMAs	through	making	1)	synthetic	compounds	that	2)	target	gene	expression;	this	model	has	the	advantage	of	being	unfamiliar	to	bacteria	and	would	act	upstream	of	current	RMA	targets,	reducing	the	very	of	the	expression	of	an	array	of	resistance	mechanisms.		While	there	are	hopeful	strides	being	made	in	new	drug	development	and	there	is	perpetual	promise	in	the	vastness	of	biochemical	space,	ultimately,	humans	cannot	outrun	bacteria	in	bacterial	evolution.	Rapid	bacterial	reproduction	(which	correlates	to	spontaneous	mutations)	aided	by	horizontal	gene	transfer	makes	bacteria	an	evolutionary	hare	compared	to	the	human	turtle.	Furthermore,	by	placing	selective	pressure	on	bacteria	we	are	inadvertently	forcing	bacteria	into	expressing	and	propagating	genes	conferring	high	levels	of	resistance.	The	most	dangerous	multi-drug	resistant	bacteria	are	nosocomial	in	origin	(clinically-acquired);	yet	the	majority	of	resistance	is	in	the	general	population	and	is	due	to	
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extensive	subtherapeutic	antibiotic	use	in	food-producing	animals	(community-acquired).	Both	clinically	and	community-acquired	resistance	contribute	to	the	demolishment	of	a	critical	building	block	(antibiotics)	of	modern	medicine.	Arguably	the	most	nonsensical	piece	of	the	puzzle	is	subtherapeutic	antibiotic	use	in	livestock,	which	accounts	for	80%	of	all	antibiotic	use	in	the	United	States1.	Not	only	are	medically	valuable	(and	currently	at-risk)	drugs	being	used	for	none-curative	purposes,	but	also	this	misuse	has	empirically	shown	to	have	negative	consequences	for	human	health	and	safety.	Furthermore,	arguably	the	continued	allowance	of	antibiotic	abuse	is	a	major	factor	in	the	perpetuation	of	inhumane	and	disease-causing	production	practices	in	agriculture.	FDA	regulations	are	seemingly	the	only	feasible	way	to	fix	the	problem,	as	other	governmental	branches,	such	as	congress,	have	balked	at	intervening	for	many	years.	Likewise,	it	is	unlikely	the	industry	giants	involved	in	antibiotic	abuse,	such	as	the	agriculture	and	pharmaceutical	industries,	would	take	it	upon	themselves	to	reduce	antibiotic	usage.	FDA,	much	to	their	credit,	unveiled	re-regulatory	measures.	And	yet,	as	the	ten-year	process	finally	shows	some	tangibility	through	re-labeled	antibiotics,	it	has	been	hugely	disappointing	and	is	arguably	barren	of	any	significant	regulatory	changes.	Although	science	is	a	beacon	of	hope	in	the	situation,	the	problem	of	antibiotic	resistance	cannot	be	fixed	by	science	alone.	This	is	a	multifaceted	issue	that	also	must	be	addressed	by	regulatory	agencies,	individuals,	and	clinicians	to	come	to	a	resolve.	The	development	of	new	antimicrobials	is	arguably	futile	if	there	are	no	regulatory	changes	or	changes	of	usage	practices.	And	yet,	in	its	futility,	we	
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have	no	choice	because	modern	medicine	is	inherently	dependent	on	antibiotics.	Finally,	while	it	will	be	difficult	to	find	a	resolve,	unlikely	it	will	come	by	waging	a	war	with	bacteria,	as	we	will	inevitably	lose,	thus	more	likely	resolve	will	be	found	at	some	level	of	symbiosis.	As	Stephen	Jay	Gould	said,		“…we	live	in	the	Age	of	Bacteria	(as	it	was	in	the	beginning,	is	now,	and	ever	shall	be,	until	the	world	ends)…”2				
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